1
|
Sheridan M, Massich M, Ashourian N. Biosimilars: From Production to Patient. JOURNAL OF INFUSION NURSING 2024; 47:19-29. [PMID: 38211611 PMCID: PMC10786443 DOI: 10.1097/nan.0000000000000528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2024]
Abstract
Biologic drugs are large, complex molecules produced through biotechnology. A biosimilar is a biologic product that is highly similar to an already approved biologic (reference product), with no clinically meaningful differences in purity, safety, or efficacy; as such, a biosimilar does not need to undergo the same level of study in a clinical trial program as the original reference product. Due to the potential impact of biosimilars on patient access and health care systems, the US Food and Drug Administration introduced an abbreviated pathway for approving biosimilars (351[k]) in 2009. There is strong evidence that switching from a reference product to a biosimilar does not reduce treatment effectiveness or increase the risk of adverse events. Biosimilars may reduce costs and increase patient access to biologic therapies. Biosimilar use in the United States has increased, as have the associated biosimilar cost savings, which are expected to reach $104 billion between 2020 and 2024. Yet, a need remains for increased knowledge among health care professionals and patients. Prescriber confidence is key to patient acceptance of biosimilars and minimizing the incidence of the nocebo effect. Infusion nurses are well positioned to help educate patients and to improve clinical outcomes across a range of diseases.
Collapse
Affiliation(s)
- Maria Sheridan
- Fresenius Kabi USA, LLC, Lake Zurich, Illinois
- Maria Sheridan, PharmD, BCNSP, is a pharmacist with inpatient and outpatient clinical experience caring for parenteral nutrition patients with conditions including cancer, autoimmune diseases, intestinal failure, and gastrointestinal and abdominal surgery complications. She spent most of her clinical practice at the Mayo Clinic Florida on a multidisciplinary team prior to transitioning to industry, where she continues to contribute to patient care through her passion for scientific education. Dr Sheridan has presented at local, state, and national professional meetings on biosimilars, pharmacy, and nutrition support topics. She previously led the oncology biosimilars Medical Science Liaison (MSL) team in Medical Affairs at Fresenius Kabi USA, focused on health care practitioner biosimilars education
- Matthew Massich, PhD, is a senior manager of US Biosimilars Medical Affairs at Fresenius Kabi USA. He is responsible for developing and executing the medical affairs strategic plan, educational initiatives, and medical communications to support the launch of biosimilar products. Dr Massich has nearly 10 years of biosimilars experience, working with multiple pharmaceutical companies to bring biologic and biosimilar products to market. He earned his PhD in Biological Sciences at Northwestern University in Evanston, Illinois, and completed postdoctoral training at Argonne National Laboratory's Center for Nanoscale Materials
- Nazanin Ashourian, PhD, was the former head of US Biosimilars Medical Affairs at Fresenius Kabi USA. She led the Medical Affairs team in the identification of data and knowledge gaps, development and execution of medical strategies, data generation, and communication of scientific/clinical information that support health care providers in clinical decision-making and patient care. Dr Ashourian received her PhD in biochemistry and molecular genetics from the Johns Hopkins University and has over 15 years of experience in scientific/clinical research, drug development, and medical strategy and communications
| | - Matthew Massich
- Corresponding Author: Matthew Massich, PhD, Fresenius Kabi USA LLC, 3 Corporate Dr, Lake Zurich, IL 60047 ()
| | - Nazanin Ashourian
- Fresenius Kabi USA, LLC, Lake Zurich, Illinois
- Maria Sheridan, PharmD, BCNSP, is a pharmacist with inpatient and outpatient clinical experience caring for parenteral nutrition patients with conditions including cancer, autoimmune diseases, intestinal failure, and gastrointestinal and abdominal surgery complications. She spent most of her clinical practice at the Mayo Clinic Florida on a multidisciplinary team prior to transitioning to industry, where she continues to contribute to patient care through her passion for scientific education. Dr Sheridan has presented at local, state, and national professional meetings on biosimilars, pharmacy, and nutrition support topics. She previously led the oncology biosimilars Medical Science Liaison (MSL) team in Medical Affairs at Fresenius Kabi USA, focused on health care practitioner biosimilars education
- Matthew Massich, PhD, is a senior manager of US Biosimilars Medical Affairs at Fresenius Kabi USA. He is responsible for developing and executing the medical affairs strategic plan, educational initiatives, and medical communications to support the launch of biosimilar products. Dr Massich has nearly 10 years of biosimilars experience, working with multiple pharmaceutical companies to bring biologic and biosimilar products to market. He earned his PhD in Biological Sciences at Northwestern University in Evanston, Illinois, and completed postdoctoral training at Argonne National Laboratory's Center for Nanoscale Materials
- Nazanin Ashourian, PhD, was the former head of US Biosimilars Medical Affairs at Fresenius Kabi USA. She led the Medical Affairs team in the identification of data and knowledge gaps, development and execution of medical strategies, data generation, and communication of scientific/clinical information that support health care providers in clinical decision-making and patient care. Dr Ashourian received her PhD in biochemistry and molecular genetics from the Johns Hopkins University and has over 15 years of experience in scientific/clinical research, drug development, and medical strategy and communications
| |
Collapse
|
2
|
Monte-Boquet E, Florez Á, Alcaín Martínez GJ, Sellas A. Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain. REUMATOLOGIA CLINICA 2023; 19:446-454. [PMID: 37805258 DOI: 10.1016/j.reumae.2022.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Accepted: 12/20/2022] [Indexed: 10/09/2023]
Abstract
OBJECTIVE To improve knowledge about biosimilar medicines and to generate a consensus framework on their use. METHODS Qualitative study. A multidisciplinary group of experts in biosimilar medicines was established (1dermatologist, 1hospital pharmacist, 1rheumatologist, and 1gastroenterologist) who defined the sections and topics of the document. A narrative literature review was performed in Medline to identify articles on biosimilar medicines. Systematic reviews, controlled, pre-clinical, clinical, and real-life studies were selected. Based on the results of the review, several general principles and recommendations were generated. The level of agreement was tested in a Delphi that was extended to 66 health professionals who voted from 1 (totally disagree) to 10 (totally agree). Agreement was defined if at least 70% of the participants voted ≥7. RESULTS The literature review included 555 articles. A total of 10 general principles and recommendations were voted upon. All reached the level of agreement established. The document includes data on the main characteristics of biosimilar medicines (definition, development, approval, indication extrapolation, interchangeability, financing, and traceability); published evidence (biosimilarity, efficacy, effectiveness, safety, immunogenicity, efficiency, switch); barriers and facilitators to its use; and data on information for patients. CONCLUSIONS Authorized biosimilar medicines meet all the characteristics of quality, efficacy, and safety. They also significantly help improve patient access to biological therapies and contribute to health system sustainability.
Collapse
Affiliation(s)
- Emilio Monte-Boquet
- Servicio de Farmacia, Hospital Universitario y Politécnico La Fe, Valencia, España.
| | - Ángeles Florez
- Servicio de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, España
| | | | - Agustí Sellas
- Servicio de Reumatología, Hospital Universitari Arnau de Vilanova, Lleida, España
| |
Collapse
|
3
|
Mahakkanukrauh A, Chaiamnuay S, Koolvisoot A, Kitamnuayphong T, Manavathongchai S, Osiri M, Louthrenoo W, Uea-Areewongsa P, Ahn K, Jung N, Kim M, Lee S, Kim H, Kim S. Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in Thailand. Immunotherapy 2023; 15:1143-1155. [PMID: 37589164 DOI: 10.2217/imt-2022-0290] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/18/2023] Open
Abstract
Background: The infliximab biosimilar CT-P13 was approved in Thailand in 2015. Methods: This open-label, multicenter, post-marketing surveillance study evaluated the safety (events of special interest [ESIs]; primary end point) and effectiveness of 46 weeks of CT-P13 treatment according to routine practice in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA), with 1 year follow-up post-treatment. Results: 30 patients were enrolled (16 RA, 8 AS and 6 PsA). Infections were the most frequently reported study drug-related ESIs (2 RA and 2 AS). One patient with RA and one with PsA experienced infusion-related reactions. No cases of tuberculosis, malignancy (as expected, given 1 year follow-up), or drug-induced liver disease were reported. Disease activity improved across indications. Conclusion: CT-P13 was well tolerated and effective across indications.
Collapse
Affiliation(s)
| | | | - Ajchara Koolvisoot
- Department of Medicine, Division of Rheumatology, Faculty of Medicine, Siriraj Hospital, Bangkoknoi, Bangkok, Thailand
| | | | - Siriporn Manavathongchai
- Department of Internal Medicine, Rheumatology Division, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand
| | - Manathip Osiri
- Department of Medicine, Division of Rheumatology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Worawit Louthrenoo
- Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Parichat Uea-Areewongsa
- Allergy & Rheumatology Unit, Division of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand
| | | | | | | | - Seulgi Lee
- Celltrion, Inc., Incheon, Republic of Korea
| | - Hanna Kim
- Celltrion, Inc., Incheon, Republic of Korea
| | | |
Collapse
|
4
|
Muth KN, Rech J, Losch FO, Hoerning A. Reversing the Inflammatory Process-25 Years of Tumor Necrosis Factor-α Inhibitors. J Clin Med 2023; 12:5039. [PMID: 37568441 PMCID: PMC10419406 DOI: 10.3390/jcm12155039] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 07/25/2023] [Accepted: 07/28/2023] [Indexed: 08/13/2023] Open
Abstract
Immune-mediated inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, peripheral and/or axial spondyloarthritis, Crohn's disease, and ulcerative colitis, are characterized by molecular and cellular changes in the immune system. Due to the systemic nature of these diseases, organs such as the liver or cardiovascular system are often affected by the inflammatory process. Tumor necrosis factor-α inhibitor therapy reduces the activation of pro-inflammatory signaling cascades, mitigates the chronic inflammatory process by restoring cellular balance, and alleviates clinical consequences, such as pain and tissue damage.
Collapse
Affiliation(s)
| | - Juergen Rech
- Department of Internal Medicine III, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany
- Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany
| | | | - André Hoerning
- Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany
- Clinic for Children and Adolescent Medicine, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany
| |
Collapse
|
5
|
Fisher A, Kim JD, Dormuth CR. Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study. Gastroenterol Res Pract 2023; 2023:2794220. [PMID: 36911254 PMCID: PMC9995207 DOI: 10.1155/2023/2794220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 02/13/2023] [Accepted: 02/15/2023] [Indexed: 03/14/2023] Open
Abstract
Background On September 5, 2019, British Columbia announced a new policy (the Biosimilars Initiative) to switch from originator to biosimilar infliximab for patients with inflammatory bowel diseases. Objective To monitor the impacts of the policy on the use of medications and health services during the first year of the policy. Methods In this population-based cohort study, we used administrative health data to construct three historical cohorts and one policy cohort of patients with inflammatory bowel diseases who used the originator infliximab. We then monitored the cumulative incidence of medications and health services. Log-likelihood ratios were used to quantify differences between the policy cohort and the average of the historical cohorts. Results The cohorts included 1839-2368 users of the originator infliximab, ages 4-90 years, mean age 43 years. During the first year of follow-up, we found: (1) a 0.9% increase in the first dispensation of infliximab, biosimilar, or originator; (2) a 16.2% increase in infliximab dose escalation; (3) a decrease of 2.4% in the dispensation of antibiotics and a 2.6% decrease in new use of prednison; (4) an anticipated increase in visits to physicians and gastroenterologists to manage switching to biosimilars (24.0%); (5) a 4.0% decrease in discharges from hospital; and (6) a 2.9% decrease in emergency admissions to hospital. Conclusion British Columbia's Biosimilars Initiative for nonmedical switching from originator to biosimilar infliximab for inflammatory bowel diseases was not associated with harmful impacts on medications and health services use. An increase in dose escalation was accompanied by an improvement in health status proxies.
Collapse
Affiliation(s)
- Anat Fisher
- Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
| | - Jason D. Kim
- Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada
| | - Colin R. Dormuth
- Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia Victoria Office, Suite 210, 1110 Government Street, Victoria, BC V8W 1Y2, Canada
| |
Collapse
|
6
|
Choquette D, Chan J, Bardi M, Whiskin C, Torani G, Smith BK, Sihota A. Monitoring the transition of patients on biologics in rheumatoid arthritis: Consensus guidance for pharmacists. Pharm Pract (Granada) 2021; 19:2377. [PMID: 34621449 PMCID: PMC8455126 DOI: 10.18549/pharmpract.2021.3.2377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Accepted: 07/04/2021] [Indexed: 12/02/2022] Open
Abstract
Background: Recent approvals for novel agents such as the small molecule Janus kinase
inhibitors (JAKi), combined with the advent of biosimilars has widened the
gamut of available therapeutic options in the treatment of rheumatoid
arthritis (RA). This combined with the introduction of mandatory non-
medical switches to biosimilars in some jurisdictions by both public and
private payors has led to a significant increase in the volume of
therapeutic changes for patients. Pharmacists are well positioned to ensure
effective and safe transitions, however there is a significant unmet need
for objective and subjective clinical guidance around therapy as well
disease state monitoring in RA that facilitates best practices throughout
the patient journey. Objective: In this paper we aim to create a consensus derived monitoring algorithm for
pharmacists to facilitate best practices throughout therapeutic transitions
from originator biologic to other originator biologics, biosimilars, and
Janus kinase inhibitors in RA. Methods: The Nominal Group Technique (NGT) was used to understand if consensus could
be found among the participants. Clinically relevant questions were
developed to capture solutions to the identified unmet need. The faculty
considered the questions as individuals, and privately generated
answers/ideas. After discussion and consideration, the participants ranked
the ideas and established a consensus. Results: Based on the outcome of the consensus discussions, an algorithm was created
to help guide pharmacists through therapeutic transitions in RA. The tool
covers important topics such as pre-transition considerations, avoiding the
nocebo effect for biosimilars, specific considerations for each drug or
class, monitoring efficacy, and when to refer. Conclusions: New classes of anti-rheumatic drugs including JAKi, along with the
introduction of biosimilars are presenting more opportunity for therapeutic
changes and monitoring in patients with RA. We hope our evidence-based
consensus derived guidance tool will assist frontline pharmacists in
supporting their patients to a successful therapeutic transition in RA.
Collapse
Affiliation(s)
- Denis Choquette
- MD. Rheumatology Institute of Montreal. Montreal, QC (Canada).
| | - Jonathan Chan
- MD. Division of Rheumatology, Department of Medicine, University of British Columbia. Vancouver, BC (Canada).
| | - Mohammad Bardi
- MD. Division of Rheumatology, Department of Medicine, University of British Columbia. Vancouver, BC (Canada).
| | - Carolyn Whiskin
- BScPharm, RPh. The Charlton Centre for Specialized Treatment. Hamilton, ON (Canada).
| | - Gabriel Torani
- BScPharm. Gabriel Torani et Habib Haddad, Pharmaciens Inc. Montreal, QC (Canada).
| | | | - Aaron Sihota
- BScPharm, RPh. Faculty of Pharmaceutical Sciences, University of British Columbia. Vancouver, BC (Canada).
| |
Collapse
|
7
|
Maccora I, Lombardi N, Crescioli G, Bettiol A, Bonaiuti R, Pagnini I, Maniscalco V, Marrani E, Mastrolia MV, Ravaldi C, Consolini R, Cattalini M, Vannacci A, Simonini G. OBSIDIAn - real world evidence of Originator to BioSImilar Drug switch in juvenile idiopathic arthritis. Rheumatology (Oxford) 2021; 61:1518-1528. [PMID: 34273158 DOI: 10.1093/rheumatology/keab572] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Revised: 06/23/2021] [Accepted: 07/05/2021] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVES Limited data about use of biosimilars are available in children with Juvenile Idiopathic Arthritis (JIA). This study therefore aimed to evaluate long-term efficacy and safety of switching from etanercept (ETA) and adalimumab (ADA) originators to their biosimilars, in children with JIA, in a real-world setting. METHODS This is a retro-prospective non-interventional multicentre Italian comparative cohort study. Medical charts of JIA children treated with biosimilars of ETA or ADA were included. Efficacy and safety of TNF-inhibitors therapy was evaluated at last follow-up during originator and at 3, 6 and 12 months following the switch to biosimilar. RESULTS 59 children (42 female, median age at onset 88 months) were treated with biosimilar of ETA (21) and ADA (38). Forty-five switched from the originator to the BIO (17 ETA, 28 ADA). At time of switch, 12/17 patients on ETA and 18/28 on ADA were in remission. No significant difference has been found at 3, 6 and 12 months after the switch. Ten patients discontinued biosimilars due to disease remission (4 ETA, 3 ADA), family willing (1 ETA), occurrence of burning at injection site (1 ETA), and persistent activity (1 ADA). No statistically significant difference was observed between originator and BIOs, nor between originator and BIOs, and between ADA and ETA in time to disease remission achievement, time to relapse and number of patients who experienced AE. CONCLUSION Our real-life results seem to confirm the efficacy and safety profile of switching from originator of ADA and ETA to their respective BIOs also in paediatric patients with JIA.
Collapse
Affiliation(s)
- Ilaria Maccora
- Rheumatology Unit, Meyer Children's University Hospital; Florence, Italy.,Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence; Florence, Italy
| | - Niccolò Lombardi
- Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence; Florence, Italy.,Tuscan Regional Centre of Pharmacovigilance; Florence, Italy
| | - Giada Crescioli
- Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence; Florence, Italy.,Tuscan Regional Centre of Pharmacovigilance; Florence, Italy
| | - Alessandra Bettiol
- Department of Experimental and Clinical Medicine, University of Florence; Florence, Italy
| | - Roberto Bonaiuti
- Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence; Florence, Italy
| | - Ilaria Pagnini
- Rheumatology Unit, Meyer Children's University Hospital; Florence, Italy
| | - Valerio Maniscalco
- Rheumatology Unit, Meyer Children's University Hospital; Florence, Italy
| | - Edoardo Marrani
- Rheumatology Unit, Meyer Children's University Hospital; Florence, Italy
| | - Maria Vincenza Mastrolia
- Rheumatology Unit, Meyer Children's University Hospital; Florence, Italy.,Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence; Florence, Italy
| | - Claudia Ravaldi
- PeaRL - Perinatal Research Laboratory, University of Florence and CiaoLapo Foundation for Perinatal Health; Florence, Italy
| | - Rita Consolini
- Section of Clinical Immunology and Rheumatology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Marco Cattalini
- Pediatrics Clinic, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy
| | - Alfredo Vannacci
- Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence; Florence, Italy.,Tuscan Regional Centre of Pharmacovigilance; Florence, Italy.,PeaRL - Perinatal Research Laboratory, University of Florence and CiaoLapo Foundation for Perinatal Health; Florence, Italy
| | - Gabriele Simonini
- Rheumatology Unit, Meyer Children's University Hospital; Florence, Italy.,Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence; Florence, Italy
| |
Collapse
|